Macau Casino Gambli...
Health Care: Drugs
Aastrom Biosciences Inc. (ASTM: NASDAQ)
$1.96 -0.03 | -1.51%
06/01/12 - 03:59 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.96 |
| 52 Week High | 3.08 |
| 52 Week Low | 1.75 |
| Avg. Daily Vol. (Mil) | 0.34 |
| Beta (3 year) | 1.05 |
| Share Related Items | |
| Mkt Cap (Mil) | 75.96 |
| Shares Out (Mil) | 38.76 |
| Float (Mil) | 38.55 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.60 |
| Current Ratio | 1.70 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 6.91K |
| Price/Book | 0.00 |
| Price/Cash Flow | -3.20 |
| Per Share Data | |
| Earnings | -0.63 |
| Sales | 0.00 |
| Book Value | 0.00 |
| Cash Flow | -0.61 |
| Business Summary | |
|---|---|
| Aastrom Biosciences, Inc. is regenerative medicine company engaged in clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on proprietary Tissue Repair Cell Technology. | |
| General Information | |
| 24 Frank Lloyd Wright Drive
P.O. Box 376 Ann Arbor, MI 48106 |
|
| www.aastrom.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 71 | |
| CEO: Timothy M. Mayleben | |
| Short Interest | |
| Current Month (Mil) | 2.72 |
| Previous Month (Mil) | 2.71 |
| Short Interest Ratio (Days) | 9.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -62.40 |
| Return on Investments | 111.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with ASTM
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- Contributor10 Cheap Biotech Stocks Tha...
- Usermrtimrx WatchList
- UserMy Folly
- Userbosw119
- Usergellis1360 Portfolio 1
- UserSusu's Stocks
- UserRet2009
- Userspecialinterest
- Userpo boy
Latest ASTM Headlines from TheStreet
- Aastrom Raises Cash To Fund Pivotal Trial 03.09.12 | 12:03 pm
- More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More 02.29.12 | 07:02 am
- Aastrom CEO: Financing Close to Completion 01.18.12 | 08:01 am
- Aastrom Cell Therapy Reverses Effects of Blocked Leg Arteries 11.14.11 | 02:11 pm
- The Next Big Thing In Biotech: Aastrom
11.11.11 | 05:11 am - Biotech Calendar: Key Dates for November 11.01.11 | 10:11 am
- Biotech Calendar: Key Dates for September 08.31.11 | 06:08 am
- 10 Cheap Biotech Stocks That Could Soar 06.28.11 | 07:06 am
- Biotech Stock Mailbag: Live Chat 06.17.11 | 11:06 am
- Biotech Stock Mailbag: Aastrom BioSciences 06.03.11 | 06:06 am
Press Releases for ASTM
Partner Headlines for ASTM
- Follow the Analyst Leader: New Stock Coverage to Watch - Wall St. Cheat Sheet 05.31.12 | 04:05 am
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Aastrom Biosciences Announces Initiation of Patient Enrollment in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T - Benzinga 02.29.12 | 04:02 pm
- 10 Biotech Stocks Undervalued By Levered Free Cash Flows - Seeking Alpha 12.07.11 | 08:12 am
- Aastrom Bio: Final RESTORE Data Looks Solid - Seeking Alpha 11.15.11 | 09:11 am
- 6 Recently Crushed Stocks With Heavy New Insider Buying - Seeking Alpha 08.14.11 | 09:08 am
- Analyst Interview - International Stem Cell - Analyst Blog - Zacks 07.27.11 | 06:07 am
- Aastrom Files At-the-Market Offering and New Shelf Registration Statement - Benzinga 06.16.11 | 04:06 pm
- Aastrom Biosciences' Trial Meets Safety and Efficacy Endpoints - Seeking Alpha 06.02.11 | 09:06 am
- 6 Speculative Biotech Stocks Smart Money Loves - Seeking Alpha 05.23.11 | 09:05 am
